San Francisco, 31
October 2018: The global smallanimal imaging (In-Vivo) market size is expected to reach
2.7 billion by 2022, according to a new report by Grand View Research, Inc.,
progressing at a CAGR of 9.0% during the forecast period. Rising number of
medical conditions requiring precise research for development of treatment
options is anticipated to stoke the demand for small animal imaging over the
forecast period.
Importance of these devices in applications
such as defining mechanism of action, drug receptor targeting, and epigenetic
research studies are projected to provide substantial growth for the market.
Some of the major drivers of small animal imaging (in-vivo) market are
technical innovations such as high-resolution MRI with other modalities,
growing number of research and pharmaceutical organizations, increasing
investments of CROs in pre-clinical studies, and rising adoption of
multi-functional pre-clinical imaging.
Access Research Report
of Small Animal Imaging (In-Vivo) Market @ www.grandviewresearch.com/industry-analysis/small-animal-imaging-in-vivo-market
Further key findings from the report suggest:
· Optical imaging was the largest segment in
2014 owing to rapid and easy operations and relatively cost-effective in comparison
to other devices
· Micro-MRI technology is anticipated to be
the fastest growing segment over the forecast period due varied applications
during anatomical and functional analysis in developing mouse embryos and
neonates
· In 2014, bio-distribution and monitoring
the treatment response dominated the market in terms of revenue
· The cancer cell detection segment is
expected to show substantial growth due to the increasing prevalence of cancer
and rising government initiatives for cancer diagnostics research
· North America was the largest region in
terms of revenue in 2016. Vast pre-clinical research, increasing demand for
rapid and advanced methods, established healthcare infrastructure, and
favorable platform for R&D pertaining to technological advancements are the
key factors driving the regional market
· Europe was the second largest region in
2014, due to a large number of clinical research and pharmaceutical
organizations and diagnostic device manufacturers
· Asia Pacific is projected to be the fastest
growing region over the forecast period owing to increasing clinical research
activities, rising base of target population, and emerging economies
· Some of the key players are Promega
Corporation, Inc.; Miltenyi Biotec GmbH; Life Technologies Corporation;
FujiFilm Holding Corporation; Siemens AG; Thermo Fisher Scientific; Bruker
Corporation; PerkinElmer Inc.; and Aspect Imaging Ltd.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the
global small animal imaging (in vivo) market on the basis of technology,
application, and region:
Small Animal Imaging (In-vivo) Technology
Outlook (Revenue, USD Million, 2012 - 2022)
·
Micro-magnetic resonance imaging
·
Optical imaging
·
Nuclear imaging
·
Other imaging modalities
Small Animal Imaging (In-vivo) Application
Outlook (Revenue, USD Million, 2012 - 2022)
·
Monitoring treatment response
·
Bio-distribution
·
Cancer cell detection
·
Biomarkers
·
Longitudinal studies
·
Epigenetics
Small Animal Imaging (In-vivo) Regional
Outlook (Revenue, USD Million, 2012 - 2022)
·
North America
·
Europe
·
Asia Pacific
·
RoW
Access Press Release of
Small Animal Imaging (In-Vivo) Market@ www.grandviewresearch.com/press-release/global-small-animal-imaging-in-vivo-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, we offer market intelligence
studies ensuring relevant and fact-based research across a range of industries,
from technology to chemicals, materials and healthcare.
No comments:
Post a Comment